RCJ enhanced colonic barrier integrity, increased SCFA-producing bacteria, activated PPAR-γ, and suppressed NFκB signaling, leading to reduced inflammatory cytokine production, indicating potential for IBD prevention and treatment 300. Here, NFKB1 is linked to irritable bowel syndrome.